Literature DB >> 16920922

Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host.

Xiao Song Liu1, Joanne Dyer, Graham R Leggatt, Germain J P Fernando, Jie Zhong, Ranjeny Thomas, Ian H Frazer.   

Abstract

The failure to mount effective immunity to virus variants in a previously virus-infected host is known as original antigenic sin. We have previously shown that prior immunity to a virus capsid protein inhibits induction by immunization of an IFN-gamma CD8+ T cell response to an epitope linked to the capsid protein. We now demonstrate that capsid protein-primed CD4+ T cells secrete IL-10 in response to capsid protein presented by dendritic cells, and deviate CD8+ T cells responding to a linked MHC class I-restricted epitope to reduce IFN-gamma production. Neutralizing IL-10 while delivering further linked epitope, either in vitro or in vivo, restores induction by immunization of an Ag-specific IFN-gamma response to the epitope. This finding demonstrates a strategy for overcoming inhibition of MHC class I epitopes upon immunization of a host already primed to Ag, which may facilitate immunotherapy for chronic viral infection or cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920922     DOI: 10.4049/jimmunol.177.5.2873

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques.

Authors:  Diane L Bolton; Kaimei Song; Georgia D Tomaras; Srinivas Rao; Mario Roederer
Journal:  Vaccine       Date:  2016-12-29       Impact factor: 3.641

Review 2.  Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management.

Authors:  Guoying Ni; Tianfang Wang; Lin Yang; Yuejian Wang; Xiaosong Liu; Ming Q Wei
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

3.  Why do adaptive immune responses cross-react?

Authors:  Karen J Fairlie-Clarke; David M Shuker; Andrea L Graham
Journal:  Evol Appl       Date:  2008-12-08       Impact factor: 5.183

4.  Non-responders to topical imiquimod followed by vaccination therapy in VIN patients may be due to the level of IL10.

Authors:  X S Liu
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

5.  LAPTM4B-35 protein is a weak tumor-associated antigen candidate.

Authors:  Guilan Shi; Chunxia Zhou; Dongmei Wang; Wenbo Ma; Shuren Zhang
Journal:  Exp Ther Med       Date:  2013-11-26       Impact factor: 2.447

6.  Attenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells.

Authors:  Priya Sakthivel; Marcus Gereke; Angele Breithaupt; Dietmar Fuchs; Luca Gigliotti; Achim D Gruber; Umberto Dianzani; Dunja Bruder
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

7.  Investigation the Possibility of Using Peptides with a Helical Repeating Pattern of Hydro-Phobic and Hydrophilic Residues to Inhibit IL-10.

Authors:  Guoying Ni; Shu Chen; Yuedong Yang; Scott F Cummins; Jian Zhan; Zhixiu Li; Bin Zhu; Kate Mounsey; Shelley Walton; Ming Q Wei; Yuejian Wang; Yaoqi Zhou; Tianfang Wang; Xiaosong Liu
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 8.  Thyroid Autoantibodies Display both "Original Antigenic Sin" and Epitope Spreading.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Front Immunol       Date:  2017-12-20       Impact factor: 7.561

9.  Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice.

Authors:  Guoying Ni; Zaowen Liao; Shu Chen; Tianfang Wang; Jianwei Yuan; Xuan Pan; Kate Mounsey; Shelley Cavezza; Xiaosong Liu; Ming Q Wei
Journal:  BMC Immunol       Date:  2017-08-15       Impact factor: 3.615

Review 10.  Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task.

Authors:  Guoying Ni; Lu Zhang; Xiaodan Yang; Hejie Li; Bowei Ma; Shelley Walton; Xiaolian Wu; Jianwei Yuan; Tianfang Wang; Xiaosong Liu
Journal:  Hum Vaccin Immunother       Date:  2020-03-11       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.